Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.WellGen, a US-based life science company, has appointed Roderick Carter as its new president and CEO.
Subscribe to our email newsletter
Dr Carter takes over from Robert Bertoldi, who was serving as interim CEO. Mr Bertoldi will continue in his WellGen board position and as president and CFO of Amphion Innovations, a significant shareholder in WellGen.
Since 2008, Dr Carter has been principal at Aquila Life Sciences, a consulting firm. Before that Dr Carter was vice president of clinical development from 2007-2008 at Reliant Pharmaceuticals USA, which is a wholly owned subsidiary of GlaxoSmithKline.
Mr Bertoldi said, “Roddy Carter’s range of experience, along with his significant achievements in medicine, research, and pharmaceutical development and commercialization, fits perfectly with WellGen as we develop medical foods using our Alignomx research model. We are very pleased to have him join the team as the company rolls out its first commercial products and continues its clinical research to develop additional products.”